Sign in
Not yet taking people in NorwayPhase 2

Oxytocin nasal spray for social and repetitive behaviors in young people with autism

Tests oxytocin nasal spray against placebo in young people with autism spectrum disorder.

Key facts

Who runs it
Oslo University Hospital HF
Where
Oslo, NorwaySee the site
Registry title
Intranasal oxytocin in youth with autism
Status
Not yet recruiting
Phase
Phase 2
People taking part
128 people, planned
Started
1 Jun 2024
Planned end
1 Mar 2026
Type of study
Interventional
Record updated
4 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for young people aged 12 to 20 with a confirmed diagnosis of autism spectrum disorder. It tests an oxytocin nasal spray taken twice a day for four weeks.

Age
12 to 20 years, both included
Sex
Males and females can join
Disease stage
Confirmed autism spectrum disorder (ASD), diagnosed with the Autism Diagnostic Observation Schedule (ADOS). Full scale IQ of 70 or more.
Earlier treatment
No new medicines or formal cognitive/behavioral therapies. Ones taken for at least 4 weeks are not counted as new. No other trial with an investigational medicine or device within 3 months before randomisation.

Main reasons for not taking part

  • Previous nasal disease or surgery, or dependence on inhaled drugs
  • Current significant nasal congestion due to a common cold
  • Significant history of liver, kidney, hormone, heart, nervous, lung, blood or metabolic disorder
  • Full scale IQ below 70
  • Pregnant or currently breastfeeding

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Male and female participant between the ages of 12 and 20, both inclusive, with a confirmed diagnosis of autism spectrum disorder (ASD) using the Autism Diagnostic Observation Schedule (ADOS)
  • Participants must be in good general physical health, as determined by the investigator
  • Participants must be able to communicate well with the Investigator, to understand and comply with the requirements of the study, and to understand the oral and written patient information
  • Provision of a signed, written informed consent, if 16 years and older. Participants between the ages of 12 and 15 (inclusive) will provide assent, with caregivers providing consent. Caregivers will also provide consent for research participation

Who cannot take part

  • Previous nasal disease, surgery, and dependence on inhaled drugs
  • Participation in any (other) clinical trial with an investigational medicinal product or medical device within 3 months prior to randomisation
  • New concomitant medications or formal cognitive/behavioral therapies. If a participant has been taking any medications or receiving formal cognitive/behavioral therapies for at least 4 weeks, then this is not considered a new therapy
  • Systemic illness requiring treatment within 2 weeks prior to Study Day 1
  • Pregnancy (self-reported or assessed by pregnancy test prior to the first administration at Experimental session 1 and 3 for all menstruating females)
  • Clinically relevant history of significant hepatic, renal, endocrine, cardiac, nervous, pulmonary, haematological or metabolic disorder
  • Known allergic reactions or hypersensitivity to any component of the study medication in the nasal spray, such as propyl parahydroxybenzoate (E216), methyl parahydroxybenzoate (E218) and chlorobutanol hemihydrate
  • Known allergic reactions or hypersensitivity/intolerance to latex
  • Other unspecified reasons that, in the opinion of the investigator or the sponsor make the participants unsuitable for enrollment
  • Current significant nasal congestion due to common colds
  • Full scale IQ < 70 (due to the prerequisite ability to complete self-report measures)
  • Currently breastfeeding

Where in Norway

  • Oslo University Hospital HFOslo, NorwayNot yet recruiting

About the trial

What the trial wants to find out

The effect of 24 IU oxytocin delivered intranasally, twice-daily, for four weeks, on social behavior and repetitive behavior.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A randomized, placebo-controlled, double-blind, 2-period cross-over study in youth with autism spectrum disorders evaluating social and repetitive behaviors after four weeks of twice daily-doses of 24IU of intranasally administered oxytocin
Plain-language title
Oxytocin nasal spray for social and repetitive behaviors in young people with autismGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
4 September 2026